Journal of Pharmacological Reports
Open Access
+44-20-4587-4809
+44-20-4587-4809
Baran Ghezelbash, Nader Shahrokhi*, Mohammad Khaksari, Gholamreza Asadikaram and Sara Shirazpour
Background/Objectives: The non-alcoholic fatty liver disease is a common cause of chronic liver disease which associated with obesity and diabetes and has a worldwide outbreak. The aim of this study cytokines and adipokines caused by NAFLD.
Methods: Thirty-five Wistar male rats after establish fatty liver models by feeding a high fat diet (HFD, 12 weeks) were randomly divided into five groups (n=7 rats/each group); control (standard diet), VEH (HFD+VEH), high dose Shilajit (HFD+250 mg/kg/day Shilajit by gavage for 2 weeks), low dose Shilajit (HFD+150 mg/kg/day Shilajit by gavage for 2 weeks), pioglitazone (HFD+10 mg/kg/day pioglitazone by gavage for 2 weeks). The serum levels of glucose, insulin, IL-1β, IL-6, TNF- α, IL-10, adiponectin and resistin were measured after the two-weeks of intervention.
Results: The results showed that in VEH group the serum levels of glucose (p<0.001), insulin (p<0.001), IL-1β (p<0.05), IL-6 (p<0.05), TNF-α (p<0.05) and resistin (p<0.01) significantly increased, while IL-10 (p<0.001) and adiponectin (p<0.01) levels decreased in comparison to the control group. However, treatments with high and low doses of Shilajit as well as pioglitazone significantly decreased insulin resistance (p<0.001), serum levels of glucose (p<0.001), IL-1β (p<0.01), TNF-α (p<0.01) and resistin (p<0.01) while increased IL-10 (p<0.001) and adiponectin (p<0.01) in comparison to VEH group.
Conclusion: The study showed that Shilajit by modulating the serum levels of cytokines, adipokines and reducing of Insulin resistance index can improve NAFLD.
Published Date: 2024-06-28; Received Date: 2020-07-22